The essence of the OSUCCC resides in its 6 Research Programs and 18 Shared Resources. It is composed of 179 full members, 38 associate and 24 introductory associate members from 13 of the 18 University colleges. Its clinical facilities include the freestanding James Cancer Hospital (JCH) as well as Nationwide Children's Hospital and now OSU East Hospital where cancer care is provided to inner city residents. To coordinate and manage an organization of this magnitude, the University supports the position of a strong CCC Director, who reports directly to the chief academic officer of the University, the Executive Vice President and Provost. Organizational capabilities of the CCC have been considerably strengthened by President Gee's appointment of Dr. Caligiuri as CEO of The James Cancer Hospital;his reporting to the President of the University, as well as his new membership on the President's Cabinet, and his continued membership on the Medical Center Executive Committee. In this capacity, Dr. Caligiuri privately meets at least monthly with President Gee, twice monthly with Provost Alutto, and at least weekly with Sr. VP Gabbe. This ensures that the Cancer Program's oversight planning and evaluation are in place and integrated within the University's strategic initiatives. These meetings assure cancer representation in the major initiatives across the University and the health system, and keep the President, Provost and Sr. VP adequately advised of all activity within the OSUCCC, including The JCH. In a large and diverse university, this organizational structure allows the Director to take maximum advantage of OSU's strengths and capabilities in promoting the cancer program agenda.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-37
Application #
8567265
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
37
Fiscal Year
2013
Total Cost
$41,151
Indirect Cost
$14,168
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Baldassari, Federica; Zerbinati, Carlotta; Galasso, Marco et al. (2018) Screen for MicroRNA and Drug Interactions in Breast Cancer Cell Lines Points to miR-126 as a Modulator of CDK4/6 and PIK3CA Inhibitors. Front Genet 9:174
Yang, Xiaosong; Pan, You; Qiu, Zhaojun et al. (2018) RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells. Clin Cancer Res 24:1629-1643
Ozawa, Patricia Midori Murobushi; Alkhilaiwi, Faris; Cavalli, Iglenir João et al. (2018) Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells. Breast Cancer Res Treat 172:713-723
Ngankeu, Apollinaire; Ranganathan, Parvathi; Havelange, Violaine et al. (2018) Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia. Oncotarget 9:4354-4365
Lopez, Cecilia M; Yu, Peter Y; Zhang, Xiaoli et al. (2018) MiR-34a regulates the invasive capacity of canine osteosarcoma cell lines. PLoS One 13:e0190086
Victor, Aaron R; Weigel, Christoph; Scoville, Steven D et al. (2018) Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development. J Immunol 200:565-572
Lampis, Andrea; Carotenuto, Pietro; Vlachogiannis, Georgios et al. (2018) MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. Gastroenterology 154:1066-1079.e5
Le Gallo, Matthieu; Rudd, Meghan L; Urick, Mary Ellen et al. (2018) The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas. Cancer 124:65-73
Jones, Jeffrey A; Mato, Anthony R; Wierda, William G et al. (2018) Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 19:65-75
Madan, Esha; Parker, Taylor M; Bauer, Matthias R et al. (2018) The curcumin analog HO-3867 selectively kills cancer cells by converting mutant p53 protein to transcriptionally active wildtype p53. J Biol Chem 293:4262-4276

Showing the most recent 10 out of 2602 publications